Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00799942

Enrollment

Registered

2008-12-01

Start date

2009-05-31

Completion date

Unknown

Last updated

2010-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Nystagmus, Acquired, Nystagmus, Congenital

Keywords

Nystagmus, congenital idiopathic

Brief summary

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Interventions

DRUGNeramexane mesylate

open-label treatment of 36 months Neramexane mesylate up to 75 mg per day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 81 Years

Healthy volunteers

Inclusion criteria

* patients who has succesfully completed the lead-in study MRZ 92579-0707/1

Exclusion criteria

* Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)

Design outcomes

Primary

Measure	Time frame
Long-term safety, Visual acuity	Baseline, week 4, month 3, 6, 9, 12, 18, 24, 30, 36 and follow-up

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026